

# Diabetic Retinopathy - Competitive Landscape, Pipeline and Market Analysis, 2017

<https://marketpublishers.com/r/D3DD97D12E7EN.html>

Date: November 2017

Pages: 100

Price: US\$ 6,950.00 (Single User License)

ID: D3DD97D12E7EN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's Diabetic Retinopathy - Competitive Landscape, Pipeline and Market Analysis, 2017 report provides an overview of the epidemiology trends of Diabetic Retinopathy in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes the historical and forecasted epidemiology data for Diabetic Retinopathy prevalent or incident cases segmented by age, sex and subpopulations. The report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Diabetic Retinopathy. Further, therapeutic assessment of pipeline products by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates are covered in this report. A comprehensive review of the market trends, drivers, barriers, key company profiles including its business and product developments are also detailed here. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight's team of industry experts.

## KEY COVERAGE AND BENEFITS

The report will help in developing business strategies by understanding the trends shaping and driving the global Diabetic Retinopathy market

Identifying prevalent patient populations as well as risk factors in the global Diabetic retinopathy market will help to improve product design, pricing, and launch plans

To understand the current pipeline scenario of different companies so as to make the research activity more robust and competitive

To understand the future market competition in the global Diabetic Retinopathy market and Insightful review of the key market drivers and barriers

The report also covers the detailed global historical and forecasted Diabetic Retinopathy market covering United States, European Union 5 (EU5 - Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023

## Contents

Report Introduction

Diabetic Retinopathy (DR) Market Overview at a Glance

Global Market Size of DR in 2016

Global Market Size of DR in 2023

Diabetic Retinopathy: Overview

Stages

Symptoms

Types

Pathophysiology

Etiology

Risk Factors

Disease Burden

Unmet Needs

Epidemiology of Diabetic Retinopathy in 7MM (2013-2023)

United States

Sex Specific Prevalence of Diabetes Retinopathy in US

Age-Specific Prevalence of Diabetes Retinopathy in US

Sub-type Prevalence of Diabetes Retinopathy in US

EU5

United Kingdom

Sex Specific Prevalence of Diabetes Retinopathy in UK

Age-Specific Prevalence of Diabetes Retinopathy in UK

Sub-type Prevalence of Diabetes Retinopathy in UK

France

Sex Specific Prevalence of Diabetes Retinopathy in France

Age-Specific Prevalence of Diabetes Retinopathy in France

Sub-type Prevalence of Diabetes Retinopathy in France

Italy

Sex Specific Prevalence of Diabetes Retinopathy in Italy

Age-Specific Prevalence of Diabetes Retinopathy in Italy

Sub-type Prevalence of Diabetes Retinopathy in Italy

Germany

Sex Specific Prevalence of Diabetes Retinopathy in Germany

Age-Specific Prevalence of Diabetes Retinopathy in Germany

Sub-type Prevalence of Diabetes Retinopathy in Germany

Spain

Sex Specific Prevalence of Diabetes Retinopathy in Spain

Age-Specific Prevalence of Diabetes Retinopathy in Spain  
Sub-type Prevalence of Diabetes Retinopathy in Spain  
Japan  
Sex Specific Prevalence of Diabetes Retinopathy in Japan  
Age-Specific Prevalence of Diabetes Retinopathy in Japan  
Sub-type Prevalence of Diabetes Retinopathy in Japan  
Treatment Algorithm  
Global Diabetic Retinopathy: Country-Wise Market Analysis  
Total Market Size of Diabetic Retinopathy (2013-2023)  
United States  
EU5  
United Kingdom  
Germany  
France  
Italy  
Spain  
Japan  
Competitive Landscape  
Marketed Drugs  
EYLEA  
Description  
Regulatory Milestones  
Advantages and Disadvantages  
Product Profile  
Safety & Efficacy  
Side effects of EYLEA  
Other Marketed Drug profiles in detailed report  
Pipeline Therapeutics  
An Overview of Pipeline Products for Diabetic Retinopathy and Diabetic Macular Edema  
Comparative Analysis  
Pipeline Therapeutics  
Pipeline Therapeutics Overview  
Late Stage Products (Filed and Phase III)  
Comparative Analysis  
Mid Stage Products (Phase II)  
Comparative Analysis  
Early Stage Products (Phase I and IND)  
Comparative Analysis  
Pre-Clinical and Discovery Products

Comparative Analysis  
Drug Candidate Profile  
Emixustat HCl: Acucela Inc.  
Product Description  
Research and Development  
Other Development Activities (Deals and Partnership )  
Other Pipeline Drug profiles in detailed report  
Therapeutic Assessment  
Assessment by Product Type  
Assessment by Phase for Monotherapy  
Assessment by Phase for Combination therapy  
Assessment by Molecule Type  
Assessment by Stage and Molecule Type  
Assessment by Route of Administration  
Assessment by Stage and Route of Administration  
Dormant Products  
Discontinued Products  
Analyst's Insights  
Market Drivers  
Market Barriers  
Appendix  
Report Methodology  
Consulting Services  
Disclaimer  
About DelveInsight

## List Of Tables

### LIST OF TABLES

Table 1: Prevalent Population of Diabetic Retinopathy in United States (2013-2023)

Table 2: Sex Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)

Table 3: Age-Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)

Table 4: Sub-type Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)

Table 5: Prevalent Population of Diabetic Retinopathy in United Kingdom (2013-2023)

Table 6: Sex Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)

Table 7: Age-Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)

Table 8: Sub-type Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)

Table 9: Prevalent Population of Diabetic Retinopathy in France (2013-2023)

Table 10: Sex Specific Prevalence of Diabetes Retinopathy in France (2013-2023)

Table 11: Age-Specific Prevalence of Diabetes Retinopathy in France (2013-2023)

Table 12: Sub-type Specific Prevalence of Diabetes Retinopathy in France (2013-2023)

Table 13: Prevalent Population of Diabetic Retinopathy in Italy (2013-2023)

Table 14: Sex Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)

Table 15: Age-Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)

Table 16: Sub-type Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)

Table 17: Prevalent Population of Diabetic Retinopathy in Germany (2013-2023)

Table 18: Sex Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)

Table 19: Age-Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)

Table 20: Sub-type Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)

Table 21: Prevalent Population of Diabetic Retinopathy in Spain (2013-2023)

Table 22: Sex Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)

Table 23: Age-Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)

Table 24: Sub-type Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)

Table 25: Prevalent Population of Diabetic Retinopathy in Japan (2013-2023)

Table 26: Sex Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)

Table 27: Age-Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)

Table 28: Sub-type Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)

Table 29: Total Market size of Diabetic Retinopathy in USD Billion (2013-2023)

Table 30: United States Market Size of Diabetic Retinopathy in USD, Billion

(2013-2023)

Table 31: United Kingdom Market Size of Diabetic Retinopathy in USD, Billion

(2013-2023)

Table 32: Germany Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Table 33: France Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Table 34: Italy Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Table 35: Spain Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Table 36: Japan Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Table 37: Pipeline Therapeutics for Diabetic Retinopathy Drugs, 2017

Table 38: Comparative Table for Diabetic Retinopathy Drugs, 2017

Table 39: Late Stage Products (Filed and Phase III), 2017

Table 40: Mid Stage Products (Phase II), 2017

Table 41: Early Stage Products (Phase I), 2017

Table 42: Pre-Clinical and Discovery Products, 2017

Table 49: Therapeutic Assessment, 2017

Table 50: Dormant Products, 2017

Table 51: Discontinued Products, 2017

## List Of Figures

### LIST OF FIGURES

Figure 1: Risk Factors of Diabetic Retinopathy

Figure 2: Prevalent Population of Diabetic Retinopathy in United States (2013-2023)

Figure 3: Sex Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)

Figure 4: Age-Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)

Figure 5: Sub-type Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)

Figure 6: Prevalent Population of Diabetes Retinopathy in United Kingdom (2013-2023)

Figure 7: Sex Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)

Figure 8: Age-Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)

Figure 9: Sub-type Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)

Figure 10: Prevalent Population of Diabetic Retinopathy in France (2013-2023)

Figure 11: Sex Specific Prevalence of Diabetes Retinopathy in France (2013-2023)

Figure 12: Age-Specific Prevalence of Diabetes Retinopathy in France (2013-2023)

Figure 13: Sub-type Specific Prevalence of Diabetes Retinopathy in France (2013-2023)

Figure 14: Prevalent Population of Diabetic Retinopathy in Italy (2013-2023)

Figure 15: Sex Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)

Figure 16: Age-Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)

Figure 17: Sub-type Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)

Figure 18: Prevalent Population of Diabetic Retinopathy in Germany (2013-2023)

Figure 19: Sex Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)

Figure 20: Age-Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)

Figure 21: Sub-type Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)

Figure 22: Prevalent Population of Diabetic Retinopathy Spain (2013-2023)

Figure 23: Sex Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)

Figure 24: Age-Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)

Figure 25: Sub-type Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)

Figure 26: Prevalent Population of Diabetic Retinopathy in Japan (2013-2023)

Figure 27: Sex Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)

Figure 28: Age-Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)



Figure 29: Sub-type Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)

Figure 30: Total Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Figure 31: United States Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Figure 32: United Kingdom Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Figure 33: Germany Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Figure 34: France Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Figure 35: Italy Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Figure 36: Spain Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Figure 37: Japan Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)

Figure 38: Marketed and Pipeline drugs for Diabetic Retinopathy, 2017

Figure 39: Vyndaqel Historical and forecasted Global Market Size in USD, Million (2016-2022)

Figure 40: Total Products for Diabetic Retinopathy, 2017

Figure 41: Late Stage Products (Filed and Phase III), 2017

Figure 42: Mid Stage Products (Phase II), 2017

Figure 43: Early Stage Products (Phase I), 2017

Figure 44: Pre-Clinical and Discovery Products, 2017

Figure 45: Patisiran Forecasted Sales in USD, Million (2018-2022)

Figure 46: Number of Monotherapy Products for Diabetic Retinopathy, 2017

Figure 47: Number of Combination Therapy Products for Diabetic Retinopathy, 2017

Figure 48: Percentage of pipeline drugs by Molecule Type (%), 2017

Figure 49: Assessment by Stage and Molecule Type, 2017

Figure 50: Pipeline Drugs by Route of Administration, 2017

Figure 51: Assessment by Stage and Route of Administration, 2017

Figure 52: Dormant Products, 2017

## I would like to order

Product name: Diabetic Retinopathy - Competitive Landscape, Pipeline and Market Analysis, 2017

Product link: <https://marketpublishers.com/r/D3DD97D12E7EN.html>

Price: US\$ 6,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D3DD97D12E7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970